Compare NTHI & HYPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTHI | HYPR |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.6M | 94.7M |
| IPO Year | N/A | 2021 |
| Metric | NTHI | HYPR |
|---|---|---|
| Price | $3.44 | $0.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $15.00 | $1.59 |
| AVG Volume (30 Days) | 65.4K | ★ 1.0M |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,563,000.00 |
| Revenue This Year | N/A | $50.75 |
| Revenue Next Year | N/A | $29.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.22 |
| 52 Week Low | $3.01 | $0.85 |
| 52 Week High | $12.99 | $2.22 |
| Indicator | NTHI | HYPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.86 | 32.37 |
| Support Level | $3.01 | $0.88 |
| Resistance Level | $4.59 | $1.19 |
| Average True Range (ATR) | 0.38 | 0.07 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 25.55 | 16.34 |
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.